Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Dana-Farber and Weill Cornell's AI tools be adopted by a major hospital network for clinical use by end of 2024?
Yes • 50%
No • 50%
Official announcements from Dana-Farber, Weill Cornell, or the adopting hospital network
Dana-Farber and Weill Cornell Develop AI Tools to Enhance Digital Pathology
Jul 11, 2024, 07:13 AM
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed new artificial intelligence (AI) tools tailored to digital pathology. These tools utilize high-resolution digital images created from tissue samples to help diagnose diseases and guide treatment. The collaboration aims to enhance diagnostic precision and efficiency through AI-pathologist synergy. Researchers, including Gabrielle Campanella and Thomas Fuchs from Icahn School of Medicine at Mount Sinai, have benchmarked eight pathology foundation models, such as UNI, Virchow, and Prov-GigaPath, on large-scale datasets for clinical diagnosis and biomarker discovery. The project also involves MohamedOmarMD, renato_umeton, and TheLancet. Additionally, a digital pathology framework called nuclei has been developed to further boost diagnostic accuracies. This development is part of a growing field that leverages AI to improve healthcare outcomes.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Fred Hutch • 25%
Dana-Farber Cancer Institute • 25%
Memorial Sloan Kettering Cancer Center • 25%
Johns Hopkins Kimmel Cancer Center • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Prov-GigaPath • 25%
UNI • 25%
nuclei • 25%
Virchow • 25%
Other • 25%
A major hospital network (e.g., Mayo Clinic) • 25%
A major pharmaceutical company (e.g., Pfizer, Merck) • 25%
A major tech company (e.g., Google, Microsoft) • 25%